If this message does not appear correctly, click this link

Speeches & Conferences

May 08  Explore biomarker-driven patient stratification at Clinical Trial Supply Chain Meeting in Singapore

Biomarker-driven personalized medicine is rapidly changing the design of clinical trials by focusing on a narrowed patient population to increase the success rate of the trial. The Clinical Trial Supply Chain Strategy Meeting is being held in Singapore on May 8th to examine patient recruitment in clinical trial from the perspectives of molecular diagnostics. Dr. Maarja-Liisa Nairismagi, ACT Genomics’ Medical Science Liaison, will moderate a roundtable discussion to examine both the implementation hurdles and the value of molecular-driven patient stratification. More details on the event: https://proventainternational.com/ctsc-apac/

Image title

Mar 17  ACT Genomics hosts Rare Cancer Symposium in Taipei to look for more solutions

Diagnosing and treating patients with rare cancer often pose significant challenges for clinicians due to lack of treatment guidelines and clinical trials. Comprehensive genomic profiling offers an opportunity to identify more treatment options based on the patient’s genotype. ACT Genomics is hosting a Rare Cancer Symposium in Taipei on March 17th to examine the application of comprehensive genomic profiling in rare cancer management. Through case-sharing and discussion of clinical challenges, the symposium aims to pool knowledge and resources to provide better care for patients of rare cancers.

Mar 05   ACT Genomics discusses using TMB as a biomarker for hematological malignancies at Singapore General Hospital

ACT Genomics is conducting a scientific talk at the Department of Hematology in Singapore General Hospital on March 5th. Our Medical Science Liaison, Dr. Maarja-Liisa Nairismagi, will share her knowledge on the genetics of hematological malignancies and the usage of tumor mutational burden (TMB) as a biomarker.

Feb 28    ACT Genomics invited to speak at Shanghai immunotherapy conference

Immunotherapy, although often considered the most promising cancer therapy in decades, still faces major challenges in identifying patients most likely to respond. Tigermed and Teddy Clinical Research Laboratory (Shanghai) hosted a conference in Shanghai on Feb. 28th to discuss the role precision medicine plays in immunotherapy. ACT Genomics’ Chief Scientific Officer, Dr. Shu-Jen Chen, talked about ACT Genomics’ experiences on evaluating immunotherapy with genomic profiling in Asia Pacific.

Image title

Feb 07-08   ACT Genomics shared insights at "Future of Personalized and Precision Medicine" Conference in Singapore

Dr. Allen Lai, ACT Genomics’ senior VP, spoke at the “Future of Personalized and Precision Medicine” conference in Singapore on Feb. 7th as a keynote speaker and discussed the complexities and clinical implementation of cancer genomics in Asia. Dr. Poon Song Ling, ACT Genomics’ Medical Science Liaison, joined a few other panelists to explore how precision medicine is transforming current healthcare model from hospital-centric to patient-centric and the advancement of precision medicine from novelty to necessity. More info on the conference: http://claridenglobal.com/conference/precisionmedicine-sg-2018/

Image title

Image title

Erdafitinib may show clinical activity in urothelial cancer with FGFR alterations

Abstract: Based on the results of a phase II trial, erdafitinib, a pan-FGFR inhibitor, exhibited response in urothelial cancer patients who have progressed after standard chemotherapy with FGFR alterations. See more...

Image title

Genomic profiling can help rare cancer patients find genotype-matched therapy

Abstract: Based on the study by University of California-San Diego Moores Cancer Center, genotype-matched therapy showed clinical benefit in rare cancer patients via genomic testing. See more...

Image title

Large pedigree exome analysis showed mutations in USP45 and ARID1A are associated with multiple myeloma

Abstract: Researchers from USA and France cooperated to perform high-risk pedigree analysis on more than 2000 cases of multiple myeloma and unaffected controls using SNP arrays, and 28 patients from 11 multiple myeloma families using whole genome sequencing data. They confirmed that mutations in USP45 and ARID1A are associated with multiple myeloma. See more ...

Image title

Entrectinib, a potential targeted therapy for metastatic pancreatic cancer

Abstract: The mainstay of treatments for metastatic pancreatic cancer is chemotherapy. At the 2018 Gastrointestinal Cancers Symposium, a new targeted drug, entrectinib, shows the clinical benefit for metastatic pancreatic cancer with NTRK and ROS1 fusion. See more...

Image title

A combination therapy shows clinical benefit in BRAF V600E-mutated anaplastic thyroid cancer

Abstract: In a phase II trial, patients with BRAF V600E-mutated anaplastic thyroid cancer were treated with the dabrafenib and trametinib combination therapy. The data revealed that the combination therapy led to a greater clinical benefit and manageable toxicity in BRAF V600E-mutated anaplastic thyroid cancer. See more...

Please do not reply to this email as it is sent from a non-monitored account. To contact us, please email service@actgenomics.com.

  To unsubscribe, please enter your E-Mail :